Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 49: 505-507, 2003; 10.1373/49.3.505
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lavoinne, A.
Right arrow Articles by Cribier, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lavoinne, A.
Right arrow Articles by Cribier, A.
Related Collections
Right arrow Other Areas of Clinical Chemistry
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2003;49:505-507.)
© 2003 American Association for Clinical Chemistry, Inc.

Technical Briefs

Release of Macromolecular Cardiac Troponin I Complex after Successful Percutaneous Transluminal Coronary Angioplasty in Acute Myocardial Infarction

Alain Lavoinne1a, Bruno Cauliez1, Hélène Eltchaninoff2, Christophe Tron2 and Alain Cribier2

1 Laboratoire de Biochimie Médicale and
2 Service de Cardiologie, Hôpital Charles Nicolle, Centre Hospitalier Univisitaire et Régional de Rouen, 76031 Rouen cedex, France

aauthor for correspondence: fax 33-2-32-88-87-80, e-mail alain.lavoinne@chu-rouen.fr

The first 20% of the full text of this article appears below.

Cardiac troponin I (cTnI) has been proposed for use in early assessment of reperfusion therapy (1)(2)(3)(4). However, commercial cTnI assays may react differently depending on the circulating forms of cTnI (5). Numerous reports have focused on the existence of troponin I complexes with the two other troponin components in the bloodstream of patients with myocardial infarction (6)(7). Independent of cTnI proteolysis occurring in the bloodstream related to the existence of covalent complexes of cTnI with cardiac troponin C (cTnI-cTnC) and T (cTnT-cTnI-cTnC) (8), cTnI degradation products also occur within human myocardium (9). To our knowledge however, no report has identified the cTnI forms released in patients with acute myocardial infarction (AMI) undergoing reperfusion therapy. Our purpose was to study cTnI release in patients undergoing successful (TIMI 3) reperfusion by primary percutaneous transluminal coronary angioplasty (PTCA) with stenting to ascertain and visualize rapid restoration of the coronary flow.

We first established the release characteristics of cTnI and creatine kinase MB (CK-MB) in 11 AMI patients [9 males and 2 females; age range, 51–80 years; 4 with an occluded right coronary artery (RCA), and 7 with an occluded left anterior descending artery (LAD)] undergoing PTCA who presented within 6 h after onset of chest pain (2–6h). All patients received standardized adjunctive therapy consisting in abciximab, heparin, clopidogrel, and aspirin. Plasma (heparin) cTnI (10) and CK-MB concentrations were measured on the DPC Immulite [upper reference limit (URLs): cTnI, 1 µg/L . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Association for Clinical Chemistry.